Overview: BSI-045B is a best-in-class high-affinity humanized anti-TSLP monoclonal antibody with over 150-fold higher in vitro efficacy compared to Tezepelumab (Tezspire™). TSLP is crucially important for mediating type 2 immunity at barrier surfaces and has been linked to widespread allergic and inflammatory diseases, such as atopic dermatitis, asthma, allergy, etc. And is anticipated to have synergistic effects in combination with IL-4 and IL-13 through IL-4R. Recent research also suggests that TSLP plays an important role in tumor survival and growth which makes it a potential target for oncology indications. BSI-045B was created by Biosion under a collaboration with CTTQ in Dec 2017. CTTQ owns Greater China rights while Biosion retains all ex-China rights to develop and commercialize for all indications.
Development status: CTTQ is currently conducting a Phase 2 clinical study of BSI-045B in severe asthma in China. Biosion is conducting a Phase 1b clinical study in atopic dermatitis in Australia.